THERAVANCE BIOPHARMA INC
Theravance Biopharma, Inc. (NASDAQ: TBPH) is a small-cap biopharmaceutical company focused on discovering, developing and commercialising medicines, primarily in respiratory disease and other specialty areas. With a market capitalisation of about $705.6 million, the company can show higher price volatility than larger peers. Investors typically watch clinical trial readouts, regulatory milestones and partner collaborations closely, as these events often drive short‑term movements and shape longer‑term commercial prospects. Revenue streams may include product sales, royalties, milestone payments and collaboration income, which can be lumpy. Biopharma development carries scientific, regulatory and commercial risks—setbacks in trials or approval processes can materially affect value. This summary is for educational purposes only and not personalised investment advice; it is important to consider diversification and consult a qualified financial adviser before making investment decisions.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Theravance Biopharma's stock with a target price of $20.83, indicating potential growth.
Financial Health
Theravance Biopharma is generating modest revenue and cash flow, but growth potential remains uncertain.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
AbbVie
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
AMGEN INC
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
APELLIS PHARMACEUTICALS INC
Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune diseases.
Baskets Featuring TBPH
Beyond The Patent Cliff: Pharma's New Growth Engines
AbbVie raised its profit outlook, proving it can thrive after its blockbuster Humira faced competition. This creates an investment opportunity in resilient pharmaceutical companies that are successfully launching new drugs to replace older ones.
Published: August 1, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Catalysts
Clinical readouts and regulatory milestones can move the stock significantly, though outcomes are uncertain and may change investor expectations quickly.
Commercial Progress
Market uptake of any approved products and the strength of partner collaborations influence revenue, but commercial execution and competition are risks to monitor.
Partnering & Royalties
Collaborations and royalty streams can help fund development and de‑risk programmes, yet they depend on partners' performance and can produce irregular income.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
